A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer

Background: We evaluated the efficacy and safety of gemcitabine in combination with erlotinib and S-1 for the treatment of advanced pancreatic cancer. Methods: Chemotherapy-naïve patients with pathologically-proven locally advanced, recurrent, or metastatic pancreatic adenocarcinoma were assessed fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Boram, Kim, Bum Jun, Kim, Hyeong Su, Choi, Dae Ro, Shim, Byoung Yong, Lee, Kyung Hee, Kim, Jin Won, Kim, Jung Han, Song, Hunho, Kim, Jong Hyeok, Park, Choong Kee, Lee, Jung Woo, Kim, Min-Jeong, Zang, Dae Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778528/
https://www.ncbi.nlm.nih.gov/pubmed/33403047
http://dx.doi.org/10.7150/jca.50514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778528/
https://www.ncbi.nlm.nih.gov/pubmed/33403047
http://dx.doi.org/10.7150/jca.50514

Ejemplares similares